OmniAb Business Combination Approved by APAC Shareholders

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. GOOGL
9. RTX
10. S

Go back to OmniAb Business Combination Approved by APAC Shareholders

Ligand Pharma (LGND) PT Lowered to $135 at H.C. Wainwright

October 25, 2022 10:47 AM EDT

H.C. Wainwright analyst Joseph Pantginis lowered the price target on Ligand Pharma (NASDAQ: LGND) to $135.00 (from $310.00) while maintaining a Buy rating.

The analyst commented, "Yesterday, Ligand announced that the combination between OmniAb and Avista Public Acquisition Corp. II (AHPA; not rated) was... More